Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

M. Bolla, Laurence Collette, L.E.C.M. Blank et al. · The Lancet · 2002 · 1.7K citations

Medicine, Oncology, Urology +17

Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

Marc Colombel, Fraser Symmans, Sixtina Gil et al. · PubMed · 1993 · 595 citations

Medicine, Cancer Biology, Oncology +14

Implication of cell kinetic changes during the progression of human prostatic cancer.

R. Berges, Jasminka Vukanovic, Jonathan I. Epstein et al. · PubMed · 1995 · 347 citations

Medicine, Cell Biology, Oncology +17

COMBINED ORCHIECTOMY AND EXTERNAL RADIOTHERAPY VERSUS RADIOTHERAPY ALONE FOR NONMETASTATIC PROSTATE CANCER WITH OR WITHOUT PELVIC LYMPH NODE INVOLVEMENT: A PROSPECTIVE RANDOMIZED STUDY

Torvald Granfors, Hans Modig, Jan‐Erik Damber et al. · The Journal of Urology · 1998 · 220 citations

Medicine, Oncology, Urology +14

Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation.

R. Berges, Yuzo Furuya, Lee Ann Remington et al. · Proceedings of the National Academy of Sciences · 1993 · 198 citations

Life Sciences, Cell Biology, Endocrinology +17